Yeast unfolds the road map toward α-synuclein-induced cell death

Cell Death and Differentiation

Volumn 17, Issue 5, 2010, Pages 746-753

  Franssens, V ^a   Boelen, E ^a   Anandhakumar, J ^a   Vanhelmont, T ^a   Buttner S ^b   Winderickx, J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

A syn; Apoptosis; Oxidative stress; Parkinson?s disease; Vesicular trafficking; Yeast

Indexed keywords

ALPHA SYNUCLEIN; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; PARKIN; REACTIVE OXYGEN METABOLITE; SERINE PROTEINASE OMI; SNARE PROTEIN;

ALZHEIMER DISEASE; CELL DEATH; CELL PROTECTION; CELL TRANSPORT; CYTOTOXICITY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUNTINGTON CHOREA; LEWY BODY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; SACCHAROMYCES CEREVISIAE; YEAST CELL;

ALPHA-SYNUCLEIN; ANIMALS; APOPTOSIS; HUMANS; MODELS, BIOLOGICAL; OXIDATIVE STRESS; PARKINSON DISEASE; YEASTS;

EUKARYOTA; SACCHAROMYCES CEREVISIAE; SACCHAROMYCETALES;

EID: 77950854717     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.203     Document Type: Review

References (80)

1. Naidoo N. ER and aging-protein folding and the ER stress response. Ageing Res Rev 2009; 8: 150-159.
2. Meriin AB, Sherman MY. Role of molecular chaperones in neurodegenerative disorders. Int J Hyperthermia 2005; 21: 403-419.
3. Ding WX, Yin XM. Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome. Autophagy 2008; 4: 141-150.
4. Limon-Pacheco J, Gonsebatt ME. The role of antioxidants and antioxidant-related enzymes in protective responses to environmentally induced oxidative stress. Mutat Res 2009; 674: 137-147.
5. Halliwell B. Proteasomal dysfunction: a common feature of neurodegenerative diseases? Implications for the environmental origins of neurodegeneration. Antioxid Redox Signal 2006; 8: 2007-2019.
6. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006; 97: 1634-1658.
7. Paschen W, Mengesdorf T. Endoplasmic reticulum stress response and neurodegeneration. Cell Calcium 2005; 38: 409-415.
8. Cebollero E, Reggiori F. Regulation of autophagy in yeast Saccharomyces cerevisiae. Biochim Biophys Acta 2009; 1793: 1413-1421.
9. Temple MD, Perrone GG, Dawes IW. Complex cellular responses to reactive oxygen species. Trends Cell Biol 2005; 15: 319-326.
10. Haynes CM, Caldwell S, Cooper AA. An HRD/DER-independent ER quality control mechanism involves Rsp5p-dependent ubiquitination and ER-Golgi transport. J Cell Biol 2002; 158: 91-101.
11. Hol EM, Scheper W. Protein quality control in neurodegeneration: walking the tight rope between health and disease. J Mol Neurosci 2008; 34: 23-33.
12. Koutsilieri E, Scheller C, Grunblatt E, Nara K, Li J, Riederer P. Free radicals in Parkinson's disease. J Neurol 2002; 249 (Suppl 2): II1-II5.
13. Chen Q, Thorpe J, Ding Q, El-Amouri IS, Keller JN. Proteasome synthesis and assembly are required for survival during stationary phase. Free Radic Biol Med 2004; 37: 859-868.
14. Fabrizio P, Longo VD. The chronological life span of Saccharomyces cerevisiae. Methods Mol Biol 2007; 371: 89-95.
15. Tofaris GK, Spillantini MG. Physiological and pathological properties of a-synuclein. Cell Mol Life Sci 2007; 64: 2194-2201.
16. Yang YX, Wood NW, Latchman DS. Molecular basis of Parkinson's disease. Neuroreport 2009; 20: 150-156.
17. Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ et al. Synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 2006; 26: 11915-11922.
18. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC. Synuclein cooperates with CSPa in preventing neurodegeneration. Cell 2005; 123: 383-396.
19. Souza JM, Giasson BI, Lee VM, Ischiropoulos H. Chaperone-like activity of synucleins. FEBS Lett 2000; 474: 116-119.
20. Golovko MY, Barcelo-Coblijn G, Castagnet PI, Austin S, Combs CK, Murphy EJ. The role of a-synuclein in brain lipid metabolism: a downstream impact on brain inflammatory response. Mol Cell Biochem 2009; 326: 55-66.
21. Uversky VN. Neuropathology, biochemistry, and biophysics of a-synuclein aggregation. J Neurochem 2007; 103: 17-37.
22. Hodara R, Norris EH, Giasson BI, Mishizen-Eberz AJ, Lynch DR, Lee VM et al. Functional consequences of a-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 2004; 279: 47746-47753.
23. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ et al. Phosphorylation of ser-129 is the dominant pathological modification of a-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006; 281: 29739-29752.
24. Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L et al. Aggregation promoting C-terminal truncation of a-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci USA 2005; 102: 2162-2167.
25. Krishnan S, Chi EY, Wood SJ, Kendrick BS, Li C, Garzon-Rodriguez W et al. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease a-synuclein fibrillogenesis. Biochemistry 2003; 42: 829-837.
26. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann Neurol 2006; 60: 389-398.
27. Olanow CW, Perl DP, De Martino GN, McNaught KS. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 2004; 3: 496-503.
28. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM. Aggresomes formed by a-synuclein and synphilin-1 are cytoprotective. J Biol Chem 2004; 279: 4625-4631.
29. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T et al. Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 2002; 322: 1089-1102.
30. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M et al. Synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000; 157: 401-410.
31. Li WW, Yang R, Guo JC, Ren HM, Zha XL, Cheng JS et al. Localization of a-synuclein to mitochondria within midbrain of mice. Neuroreport 2007; 18: 1543-1546.
32. Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB et al. Proteasomal inhibition by a-synuclein filaments and oligomers. J Biol Chem 2004; 279: 12924-12934.
33. Sugeno N, Takeda A, Hasegawa T, Kobayashi M, Kikuchi A, Mori F et al. Serine 129 phosphorylation of a-synuclein induces unfolded protein response-mediated cell death. J Biol Chem 2008; 283: 23179-23188.
34. Ryu EJ, Harding HP, Angelastro JM, Vitolo OV, Ron D, Greene LA. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J Neurosci 2002; 22: 10690-10698.
35. Levy OA, Malagelada C, Greene LA. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis 2009; 14: 478-500.
36. Yao Z, Wood NW. Cell death pathways in Parkinson's disease: role of mitochondria. Antioxid Redox Signal 2009; 11: 2135-2149.
37. Dixon C, Mathias N, Zweig RM, Davis DA, Gross DS. Synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast. Genetics 2005; 170: 47-59.
38. Zabrocki P, Pellens K, Vanhelmont T, Vandebroek T, Griffioen G, Wera S et al. Characterization of a-synuclein aggregation and synergistic toxicity with protein tau in yeast. FEBS J 2005; 272: 1386-1400.
39. Gitler AD, Bevis BJ, Shorter J, Strathearn KE, Hamamichi S, Su LJ et al. The Parkinson's disease protein a-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci USA 2008; 105: 145-150.
40. Soper JH, Roy S, Stieber A, Lee E, Wilson RB, Trojanowski JQ et al. Synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. Mol Biol Cell 2008; 19: 1093-1103.
41. Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH. Lipid rafts mediate the synaptic localization of a-synuclein. J Neurosci 2004; 24: 6715-6723.
42. Zabrocki P, Bastiaens I, Delay C, Bammens T, Ghillebert R, Pellens K et al. Phosphorylation, lipid raft interaction and traffic of a-synuclein in a yeast model for Parkinson. Biochim Biophys Acta 2008; 1783: 1767-1780.
43. Volles MJ, Lansbury Jr PT. Relationships between the sequence of a-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol 2007; 366: 1510-1522.
44. Vamvaca K, Volles MJ, Lansbury Jr PT. The first N-terminal amino acids of a-synuclein are essential for a-helical structure formation in vitro and membrane binding in yeast. J Mol Biol 2009; 389: 413-424.
45. Kim M, Jung W, Lee IH, Bhak G, Paik SR, Hahn JS. Impairment of microtubule system increases a-synuclein aggregation and toxicity. Biochem Biophys Res Commun 2008; 365: 628-635.
46. Outeiro TF, Lindquist S. Yeast cells provide insight into a-synuclein biology and pathobiology. Science 2003; 302: 1772-1775.
47. Sharma N, Brandis KA, Herrera SK, Johnson BE, Vaidya T, Shrestha R et al. Synuclein budding yeast model: toxicity enhanced by impaired proteasome and oxidative stress. J Mol Neurosci 2006; 28: 161-178.
48. Brandis KA, Holmes IF, England SJ, Sharma N, Kukreja L, DebBurman SK. Synuclein fission yeast model: concentration-dependent aggregation without plasma membrane localization or toxicity. J Mol Neurosci 2006; 28: 179-191.
49. Azeredo Da Silveira S, Schneider BL, Cifuentes-Diaz C, Sage D, Abbas-Terki T, Iwatsubo T et al. Phosphorylation does not prompt, nor prevent, the formation of a-synuclein toxic species in a rat model of Parkinson's disease. Hum Mol Genet 2009; 18: 872-887.
50. Okochi M, Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T et al. Constitutive phosphorylation of the Parkinson's disease associated a-synuclein. J Biol Chem 2000; 275: 390-397.
51. Inglis KJ, Chereau D, Brigham EF, Chiou SS, Schobel S, Frigon NL et al. Polo-like kinase 2 (PLK2) phosphorylates a-synuclein at serine 129 in central nervous system. J Biol Chem 2009; 284: 2598-2602.
52. Qing H, Wong W, McGeer EG, McGeer PL. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun 2009; 387: 149-152.
53. Kragh CL, Lund LB, Febbraro F, Hansen HD, Gai WP, El-Agnaf O et al. Synuclein aggregation and ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem 2009; 284: 10211-10222.
54. Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ et al. Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 2009; 41: 308-315.
55. Yeger-Lotem E, Riva L, Su LJ, Gitler AD, Cashikar AG, King OD et al. Bridging highthroughput genetic and transcriptional data reveals cellular responses to a-synuclein toxicity. Nat Genet 2009; 41: 316-323.
56. Matthew EM, Yen TJ, Dicker DT, Dorsey JF, Yang W, Navaraj A et al. Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle 2007; 6: 2571-2578.
57. Flower TR, Chesnokova LS, Froelich CA, Dixon C, Witt SN. Heat shock prevents a-synucleininduced apoptosis in a yeast model of Parkinson's disease. J Mol Biol 2005; 351: 1081-1100.
58. Liang J, Clark-Dixon C, Wang S, Flower TR, Williams-Hart T, Zweig R et al. Novel suppressors of a-synuclein toxicity identified using yeast. Hum Mol Genet 2008; 17: 3784-3795.
59. Fan GH, Zhou HY, Yang H, Chen SD. Heat shock proteins reduce a-synuclein aggregation induced by MPP+ in SK-N-SH cells. FEBS Lett 2006; 580: 3091-3098.
60. Auluck PK, Meulener MC, Bonini NM. Mechanisms of suppression of a-synuclein neurotoxicity by geldanamycin in Drosophila. J Biol Chem 2005; 280: 2873-2878.
61. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 reduces a-synuclein aggregation and toxicity. J Biol Chem 2004; 279: 25497-25502.
62. Shen HY, He JC, Wang Y, Huang QY, Chen JF. Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem 2005; 280: 39962-39969.
63. Lin JT, Lis JT. Glycogen synthase phosphatase interacts with heat shock factor to activate CUP1 gene transcription in Saccharomyces cerevisiae. Mol Cell Biol 1999; 19: 3237-3245.
64. Chen Q, Thorpe J, Keller JN. Synuclein alters proteasome function, protein synthesis, and stationary phase viability. J Biol Chem 2005; 280: 30009-30017.
65. Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008; 131: 1969-1978.
66. Flower TR, Clark-Dixon C, Metoyer C, Yang H, Shi R, Zhang Z et al. YGR198w (YPP1) targets A30P a-synuclein to the vacuole for degradation. J Cell Biol 2007; 177: 1091-1104.
67. Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006; 38: 1184-1191.
68. Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human a-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 2001; 276: 44284-44296.
69. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B et al. Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006; 313: 324-328.
70. Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or a-synuclein. Science 2003; 302: 1769-1772.
71. Gaeta A, Hider RC. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol 2005; 146: 1041-1059.
72. Griffioen G, Duhamel H, Van Damme N, Pellens K, Zabrocki P, Pannecouque C et al. A yeast-based model of a-synucleinopathy identifies compounds with therapeutic potential. Biochim Biophys Acta 2006; 1762: 312-318.
73. Junn E, Mouradian MM. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett 2002; 320: 146-150.
74. Uehara T. Accumulation of misfolded protein through nitrosative stress linked to neurodegenerative disorders. Antioxid Redox Signal 2007; 9: 597-601.
75. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 2006; 441: 513-517.
76. Madeo F, Carmona-Gutierrez D, Ring J, Buttner S, Eisenberg T, Kroemer G. Caspasedependent and caspase-independent cell death pathways in yeast. Biochem Biophys Res Commun 2009; 382: 227-231.
77. Madeo F, Herker E, Maldener C, Wissing S, Lachelt S, Herlan M et al. A caspase-related protease regulates apoptosis in yeast. Mol Cell 2002; 9: 911-917.
78. Lee RE, Puente LG, Kaern M, Megeney LA. A non-death role of the yeast metacaspase: Yca1p alters cell cycle dynamics. PLoS One 2008; 3: e2956.
79. Büttner S, Bitto A, Ring J, Augsten M, Zabrocki P, Eisenberg T et al. Functional mitochondria are required for a-synuclein toxicity in ageing yeast. J Biol Chem 2008; 283: 7554-7560.
80. Rappley I, Gitler AD, Selvy PE, LaVoie MJ, Levy BD, Brown HA et al. Evidence that a-synuclein does not inhibit phospholipase D. Biochemistry 2009; 48: 1077-1083.